<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141596</url>
  </required_header>
  <id_info>
    <org_study_id>LREC 03.0001</org_study_id>
    <nct_id>NCT00141596</nct_id>
  </id_info>
  <brief_title>Extracellular Fluid in Resistant Hypertension</brief_title>
  <official_title>A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St George's, University of London</source>
  <brief_summary>
    <textblock>
      The optimal treatment of drug resistant (defined as BP&gt; 140/85 despite three
      anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test
      the hypothesis that resistant hypertension is caused by excessive expansion of extracellular
      fluid volume. A secondary objective is to study which of three different antihypertensive
      drugs would be most useful in drug resistant hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR, with
      Brochner-Mortensen correction applied. Subjects then receive the following drugs, in a
      randomised fashion, for a period of four weeks each, with BP &amp; ECV measurement at end of each
      period: doxazosin GITS (Cardura XL) 4 mg b.d.; frusemide 40 mg b.d.; amiloride 5 mg b.d.;
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient accrual rate
  </why_stopped>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ECV; change in BP</measure>
  </primary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cardura XL 4 mg bd</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride 5 mg bd</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide 40 mg bd</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BP &gt;140/85

          -  3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic)

        Exclusion Criteria:

          -  Pregnancy

          -  Breast Feeding

          -  Unstable heart failure

          -  Chronic Liver Disease

          -  Creatinine &gt;120 mcmol/L

          -  Contraindication to (or intolerance of) drug used in study

          -  BP &gt; 180/110
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy WR Doulton, BSc MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGUL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood Pressure Unit, Dept. Cardiac &amp; Vascular Sciences, SGUL</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Extracellular Fluid Volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

